CAR T-Cell Therapy Approved for Multiple Myeloma
CAR T-cell therapy, specifically idecabtagene vicleucel (Abecma), was FDA-approved for multiple myeloma patients unresponsive to prior treatments. In a study, 72% of participants saw tumor reduction, with remissions lasting a median of 11 months. Despite its effectiveness, the therapy can cause severe side effects and is costly, priced at $419,500 per infusion.
Reference News
CAR T-Cell Therapy Approved for Multiple Myeloma
CAR T-cell therapy, specifically idecabtagene vicleucel (Abecma), was FDA-approved for multiple myeloma patients unresponsive to prior treatments. In a study, 72% of participants saw tumor reduction, with remissions lasting a median of 11 months. Despite its effectiveness, the therapy can cause severe side effects and is costly, priced at $419,500 per infusion.